Journal
MSPHERE
Volume 2, Issue 5, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/mSphere.00397-17
Keywords
Acinetobacter; Enterobacteriaceae; Escherichia coli; Klebsiella; ST258; MAb therapy; monoclonal antibodies; multidrug resistance
Categories
Funding
- NIAID NIH HHS [R01 AI127704, R21 AI114259] Funding Source: Medline
Ask authors/readers for more resources
With the problem of multidrug-resistant Gram-negative pathogens becoming increasingly dire, new strategies are needed to protect and treat infected patients. Though abandoned in the past, monoclonal antibody therapy against Gram-negative bacteria remains a potential solution and has potential advantages over the broad-spectrum antibiotics they were once replaced by. This Perspective reviews the prospect of utilizing monoclonal antibody therapy against these pathogens, as well as the challenges of doing so and the current therapy targets under investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available